Likewise, semaglutide, whose structure is also based on human GLP1, injected once-weekly at two doses (0.5 mg or 1.0 mg) for 104 weeks in the SUSTAIN-6 trial (NCT01720446) reduced the rate of cardiovascular death and non-fatal MI and stroke in patients with T2DM at high cardiovascular risk. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.